Articles & Guides
Expert analysis, comparisons, and ranked listicles to help you evaluate pharmaceutical services vendors.
Pharma Services Market — 2025 Update
Synthesis of three investment banking sector reports covering pharma services market trends, M&A activity, and 2025-2030 outlook across six commercialization segments.
AI Prior Authorization Vendors: Infinitus vs SuperDial vs Neon Health vs Coral AI
Head-to-head comparison of four AI-native prior authorization automation vendors targeting different segments of the pharma patient access workflow. Represents the emerging question of where AI ins...
Data & Analytics Platforms: IQVIA vs Komodo Health vs Definitive Healthcare vs ConcertAI
Head-to-head comparison of the four dominant data and analytics platforms for pharma commercial operations. Represents the ecosystem question facing procurement teams: legacy incumbent (IQVIA) vers...
Hub Services Platforms: ConnectiveRx vs AssistRx vs CareMetx vs EVERSANA
Head-to-head comparison of the four leading independent (non-wholesaler-owned) hub services platforms for specialty drug patient support. Represents the core vendor selection decision for manufactu...
Market Access Consulting: Trinity Life Sciences vs IQVIA vs Guidehouse vs Precision AQ vs Lumanity
Head-to-head comparison of the five primary market access consulting firms serving the pharma industry. Represents the key trade-offs facing commercial operations leaders: proprietary data depth ve...
Big Three PBM Specialty Pharmacy Operations
The three PBM-owned specialty pharmacies — CVS Specialty (CVS Caremark), Accredo (Express Scripts/Evernorth), and OptumRx Specialty (UnitedHealth Group) — collectively captured approximately 68% of...
ConnectiveRx vs EVERSANA: Hub Services Head-to-Head Comparison
Head-to-head comparison of ConnectiveRx and EVERSANA for hub services and patient support programs. Represents the core architectural question facing pharmaceutical buyers: focused specialist vs. f...
Hub Services Buyer's Guide 2026: Complete Vendor Evaluation Framework
Comprehensive guide for evaluating and selecting hub services vendors, built from a real-world RFP framework containing 73 evaluation questions across 12 capability domains, supplemented by PE inve...
Hub Services Market Analysis: U.S. Pharmaceutical Patient Support Programs
Comprehensive market sizing, competitive landscape, M&A activity, technology differentiation, and outlook for the U.S. pharmaceutical hub services market. Synthesized from multiple public market re...
US Pharma Services Market Sizing: Six-Category Overview
Investment-grade market sizing across six US pharma services categories spanning the commercialization value chain. Combined, these markets represent approximately $45--47 billion in 2024 US revenu...
ConnectiveRx Deep Dive: PE Perspective on Hub Services
This analysis is derived from two private equity investment committee memos (IC #1, October 31, 2022 and IC #2, November 7, 2022) prepared during the Kohlberg & Company acquisition of ConnectiveRx ...
EVERSANA Patient Services: Full-Stack Commercialization Model
This analysis is derived from EVERSANA's Patient Services General Capabilities Deck (2024), a 49-page presentation detailing their integrated patient services and commercialization platform. EVERSA...
Hub Services RFP Framework: What Pharma Buyers Evaluate
This analysis is synthesized from an actual pharma company Hub RFP Requirements Template and cross-referenced with operational details from the ConnectiveRx IC memos and EVERSANA capabilities deck....